The First Weak-lensing Analysis with the James Webb Space Telescope: SMACS J0723.3-7327

Utilizing the James Webb Space Telescope Early Release NIRCam Observations, we perform a weak-lensing analysis of the massive galaxy cluster SMACS J0723.3-7327 ($z=0.39$). We investigate the spatial variation of the PSF from the stars in the mosaic image. Our measurements show that the PSF for both modules has very small spatial and temporal variation with average complex ellipticity components of $e_1=0.007\pm0.001$ and $e_2=0.029\pm0.001$ in the observed north-up reference frame. We create PSF models through a principal component analysis of the stars and show that they properly account for the ellipticity of the PSF with residual shapes of $e_1=(0.3\pm3.5)\times10^{-4}$ and $e_2=(1.8\pm4.0)\times10^{-4}$. We select background galaxies by their photometric redshift and measure galaxy shapes by model fitting. Our weak-lensing source catalog achieves 215 galaxies arcmin$^{-2}$. We map the projected mass density of SMACSJ0723 and detect the cluster with a peak significance of $12.2\sigma$. The mass distribution is found to elongate in the east-west direction with an extension to the northeast edge of the field of view where a candidate substructure is found in the Chandra X-ray imaging. We fit the tangential shear with a Navarro-Frenk-White model and estimate the mass of the cluster to be $M_{500}=7.9\pm1.1\times10^{14}$ M$_{\odot}$ ($M_{200}=11.4\pm1.5\times10^{14}$ M$_\odot$ ), which agrees with existing mass estimates. Combining the multiwavelength evidence from literature with our weak-lensing analysis, we hypothesize that SMACSJ0723 is observed near first pericenter passage and we identify candidate radio relics.Comment: 14 pages, 11 figures, submitted to Ap

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. copy; 2011 Blackwell Verlag GmbH, Berlin.SCOPUS: ar.jFLWINinfo:eu-repo/semantics/publishe